The role of DDR pathway and its upstream components [such as DNA dependent protein kinase (DNA-PK) and ATM] as therapeutic targets in MYC driven lymphomas has been confirmed in a recent report by Johnstone and coworkers on the efficacy of combined inhibition of ATM, DNA-PK and mammalian target of rapamycin (mTOR) in Eμ-MYC lymphoma models [27]. This evidence concerns the gene ATM and lymphoma.